Shows & Panels
- AFCEA Answers
- Ask the CIO
- The Big Data Dilemma
- Carrying On with Continuity of Operations
- Connected Government
- Constituent Servicing
- Continuous Monitoring: Tools and Techniques for Trustworthy Government IT
- The Cyber Imperative
- Cyber Solutions for 2013 and Beyond
- The Data Privacy Imperative: Safeguarding Sensitive Data
- Expert Voices
- Federal Executive Forum
- Federal IT Challenge
- Federal Tech Talk
- Mission-critical Apps in the Cloud
- The Modern Federal Threat Landscape
- The Path from Legacy Systems
- The Real Deal on Digital Government
- The Reality of Continuous Monitoring... Is Your Agency Secure?
- Veterans in Private Sector: Making the Transition
Shows & Panels
Swedish doctors claim pioneering uterus transplant
Tuesday - 9/18/2012, 2:24pm EDT
STOCKHOLM (AP) - Two Swedish women are hoping to get pregnant after undergoing what doctors are calling the world's first mother-to-daughter uterus transplants.
Specialists at the University of Goteborg said they performed the surgery over the weekend without complications but added that they won't consider it successful unless the women give birth to healthy children.
"That's the best proof," said Michael Olausson, one of the surgeons.
One of the unidentified women had her uterus removed many years ago because of cervical cancer, while the other was born without a womb. Both are in their 30s.
They will undergo a year of observation before doctors attempt to help them get pregnant via in vitro fertilization, in which embryos created with eggs from their own ovaries will be implanted in their wombs.
Researchers around the world have been looking for ways to transplant wombs so that women who have lost a uterus to cancer or other diseases can become pregnant.
Fertility experts hailed the Swedish transplants as a significant step but stressed it remains to be seen whether they will result in successful pregnancies.
Even if the approach works, it is unclear how many women will choose such an option, given the risks and the extreme nature of the operation compared with, say, using a surrogate mother.
Turkish doctors last year said they performed the first successful uterus transplant, giving a womb from a deceased donor to a young woman. Olausson said that woman is doing fine, but he wasn't sure whether she has started fertility treatment.
In 2000, doctors in Saudi Arabia transplanted a uterus from a live donor, but it had to be removed three months later because of a blood clot.
Olausson said there could be a lower risk of organ rejection when the donor is a family member, but he said a more important factor is the "emotional connection" between mother and daughter.
Also, the mother-daughter procedure makes it easier to "know that the transplanted organ works," he said, adding that it doesn't matter whether the donor is past menopause.
For a year, doctors will monitor how the two patients respond to the anti-rejection drugs needed to stop their immune systems from attacking the donated wombs.
After a maximum of two pregnancies, the wombs will be removed so the women can stop taking the drugs, which can have side effects such as high blood pressure, swelling and diabetes and may also raise the risk of some types of cancer.
"There's no doubt this will be a pioneering step if it's been successful," said Scott Nelson, chairman of obstetrics and gynecology at the University of Glasgow, Scotland. "At present, the only option for these women is to have a surrogacy _ i.e., having their embryos implanted into another woman."
Nelson said a donated womb would not contain all the blood vessels it originally had, possibly compromising a baby's development.
"Pre-term birth is a major risk _ i.e., a small baby being born. That's what you'd mainly be worried about," he said.
James Grifo, an infertility expert at New York University, questioned how a fetus would be affected by the immune-suppressing drugs.
"Some people will always be willing to take the risk, but there are issues that need to be addressed before you expose a fetus to these medicines," he said. Grifo and colleagues at NYU abandoned a uterus transplant program "because some issues seemed insurmountable."
"The group of patients that would need this is so small we decided to focus our efforts elsewhere," he said. "We started in rats, but once we got to humans, it became very clear the rejection drug was going to be the issue, and we didn't know how to safely deal with that issue."
In Sweden, Olausson said anti-rejection drugs have not proved harmful to fetuses when the mother has undergone other organ transplants. Also, tests on mice, rats and pigs with transplanted wombs showed no ill effects from such drugs, he said.
AP Medical Writer Maria Cheng in London contributed to this report.
(Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)